Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Seralutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gossamer Bio Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)
    Gossamer Bio Announces Inducement Grant Under Nasdaq Rule 5635(c)(4)

    07 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241007084198/en

    BUSINESSWIRE
    07 Oct 2024
    Share Share
    Gossamer To Provide Seralutinib OLE Data At ATS 2024
    Gossamer To Provide Seralutinib OLE Data At ATS 2024

    14 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240514616477/en

    BUSINESSWIRE
    14 May 2024
    Share Share
    Chiesi and Gossamer Bio collaborate to develop Seralutinib for PAH
    Chiesi and Gossamer Bio collaborate to develop Seralutinib for PAH

    06 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chiesi-and-gossamer-bio-announce-transformative-global-collaboration-to-develop-and-commercialize-seralutinib-in-pulmonary-arterial-hypertension-and-other-respiratory-indications-302136742.html

    PR NEWSWIRE
    06 May 2024
    Share Share
    Gossamer Bio to Host Webcast to Discuss Seralutinib Open-Label Extension Data
    Gossamer Bio to Host Webcast to Discuss Seralutinib Open-Label Extension Data

    13 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231213371661/en

    BUSINESSWIRE
    13 Dec 2023
    Share Share
    Gossamer Announces Seralutinib Meets Endpoint in PII TORREY Study in PAH
    Gossamer Announces Seralutinib Meets Endpoint in PII TORREY Study in PAH

    06 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221206005388/en

    BUSINESSWIRE
    06 Dec 2022
    Share Share
    Gossamer touts phase 2 win but investors are wary
    Gossamer touts phase 2 win but investors are wary

    06 Dec 2022

    // Max Bayer FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/gossamer-touts-phase-2-win-analysts-dont-appear-interested-celebrating

    Max Bayer FIERCEBIOTECH
    06 Dec 2022
    Share Share